IGF-DES

IGF-DES (Des(1-3) Insulin-Like Growth Factor-1)

IGF-DES is a truncated analog of human Insulin-Like Growth Factor-1 (IGF-1), consisting of the 67-amino-acid form lacking the first three amino acids of the full-length sequence. This modification significantly reduces binding affinity to Insulin-Like Growth Factor Binding Proteins (IGFBPs), potentially enhancing receptor interaction and local tissue activity. It is intended solely for scientific and analytical research use.


Overview

IGF-DES is hypothesized to act through IGF-1 receptor pathways involved in cellular proliferation, differentiation, and regeneration. The removal of three N-terminal amino acids may increase receptor accessibility and local bioavailability, making IGF-DES a useful model for studying the role of IGF-1 in tissue adaptation, repair, and growth.

Research models suggest IGF-DES may influence protein synthesis, glucose uptake, and satellite cell activation in skeletal muscle. It has been explored as an analog for examining anabolic signalling, wound repair, cartilage restoration, and metabolic regulation in both in-vitro and in-vivo systems.


Chemical Makeup

• Molecular Formula: C₃₁₉H₄₉₅N₉₁O₉₆S₇ (approximate for the unmodified 67-amino-acid chain)
• Theoretical Mass: 7,365 Da
• Observed Mass (Batch # 2025015): 7,372.4 Da
• Purity (HPLC, LCMS-confirmed): 98.85 %
• Form: Lyophilized powder
• Analysis Method: Reverse-phase HPLC (UV 214 nm) and LCMS (ESI+ mode), calibrated with peptide reference standard.
• Appearance: White to off-white powder

Research and Clinical Studies

IGF-DES and Muscle Cell Activation

Studies examining IGF-DES indicate its enhanced ability to stimulate myoblast proliferation and differentiation compared with native IGF-1. This property is thought to arise from its decreased IGFBP binding, which increases the concentration of free peptide available to interact with IGF-1 receptors on muscle cells.

IGF-DES and Tissue Regeneration

Research in models of muscle and cartilage injury suggests IGF-DES may support regeneration and tissue remodelling by promoting cellular growth and differentiation pathways. These findings make it a peptide of interest in regenerative biology and growth factor signalling studies.

IGF-DES and Metabolic Signalling

Because IGF-1 and its analogues are involved in insulin-like metabolic processes, IGF-DES has been studied for its potential influence on glucose transport, lipid metabolism, and anabolic signalling in hepatic and skeletal tissues. Its short duration of action allows precise evaluation of transient growth factor responses.


Summary

IGF-DES (Batch # 2025015) has been verified by LCMS to possess a molecular mass of 7,372.4 Da and a purity of 98.85 %. Analytical data confirm the sample’s integrity and suitability for controlled laboratory studies on growth factor signalling, cellular proliferation, and tissue regeneration. This peptide is available for research and laboratory purposes only.


References

1. Walton PE, Dunshea FR, Ballard FJ. In vivo actions of IGF analogues with reduced binding to IGFBPs: metabolic and growth effects in pigs. Prog Growth Factor Res. 1995;6(2-4):385-395. https://pubmed.ncbi.nlm.nih.gov/8560745/
   
2. Wood TL, Rogler LE, Czick ME, et al. Des(1-3)IGF-I: a truncated analogue with reduced IGFBP binding and enhanced potency. J Endocrinol. 1995;147(1):75-82. https://pubmed.ncbi.nlm.nih.gov/7734334/
   
3. Sonnenschein C, Soto AM, et al. Des(1-3)IGF-I, a modified growth factor with enhanced receptor activity. Int J Biochem Cell Biol. 1996;28(9):1205-1210. https://pubmed.ncbi.nlm.nih.gov/8930132/
   
4. Yakar S, Liu JL, Stannard B, et al. Elevation of tissue IGF-I alters skeletal muscle phenotype and insulin sensitivity. J Clin Invest. 2002;110(4):457-466. https://pubmed.ncbi.nlm.nih.gov/12189246/
   
5. Stewart CEH, Rotwein P. Growth, differentiation, and survival: multiple physiological functions for IGF-I in skeletal muscle. BioEssays. 1996;18(8):631-640. https://pubmed.ncbi.nlm.nih.gov/8757937/
   
6. Adamek A, Kasprzak A. Insulin-like growth factor system in liver diseases. World J Gastroenterol. 2018;24(45):4910-4925. https://pubmed.ncbi.nlm.nih.gov/30546356/
   
7. Lee PD, Conover CA, Powell DR. Regulation and function of insulin-like growth factor binding proteins. Physiol Rev. 1993;73(3):621-654. https://pubmed.ncbi.nlm.nih.gov/8331072/
   
8. Bichell DP, Kikuchi K, Rotwein P. Growth hormone rapidly activates insulin-like growth factor-I gene transcription in vivo. Mol Endocrinol. 1992;6(11):1899-1908. https://pubmed.ncbi.nlm.nih.gov/1464608/
   
9. Sandberg-Nordqvist AC, et al. Differential effects of IGF-I and Des(1-3)IGF-I on cell proliferation. Endocrinology. 1994;134(3):1136-1142. https://pubmed.ncbi.nlm.nih.gov/8107671/
   
10. NovateinBio. Human Recombinant IGF-1 DES (1-3) Product Information. https://www.novateinbio.com/growth-factors/73528-IGF1-Human-Des1-3.html
    

For research use only. Not for human or veterinary use.